Choosing between stem cell therapy and drugs in myelofibrosis (Q34734491)

4 August 2017

1 reference

title

Choosing between stem cell therapy and drugs in myelofibrosis (English)

1 reference

4 August 2017

N Kröger

1

1 reference

4 August 2017

R A Mesa

series ordinal

2

1 reference

4 August 2017

publication date

10 January 2008

1 reference

4 August 2017

1 reference

4 August 2017

volume

22

1 reference

4 August 2017

issue

3

1 reference

4 August 2017

page(s)

474-486

1 reference

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis resear

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Long-term remission of myelofibrosis following nonmyeloablative allogeneic peripheral blood progenitor cell transplantation in older age: the Scripps Clinic experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Pros and cons of splenectomy in patients with myelofibrosis undergoing stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Clinicopathological impact of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: a concise update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Development of TGF-beta signalling inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

VEGF inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Hematopathologic findings in chronic idiopathic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Allogeneic bone marrow transplantation for primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Allogeneic bone marrow transplantation for primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Allogeneic hematopoietic stem cell transplantation for myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Stem cell transplantation for myelofibrosis: a report from two Canadian centers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Outcome of allogeneic stem cell transplantation in patients with myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Alpha-interferon in primary idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

alpha-Interferon in myelofibrosis: a case report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Ineffectiveness of interferon-gamma in the treatment of idiopathic myelofibrosis: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Lack of alteration in GATA-1 expression in CD34+ hematopoietic progenitors from patients with idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Prognostic factors in idiopathic (primary) osteomyelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405080

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2405080

1 reference

Dimensions Publication ID

4 August 2017

1028572174

0 references

1 reference